Introduction {#Sec1}
============

*Acinetobacter baumannii* is frequently associated with life-threatening nosocomial infections and also causes outbreaks particularly in intensive care units (Lee et al. [@CR17]). It is included in the six highest-urgency risky microorganisms, the ESKAPE group, by the Infectious Diseases Society of America (IDSA) (Boucher et al. [@CR2]). The increasing worldwide prevalence of multi-drug resistant (MDR) *A. baumannii*, particularly carbapenem-resistant (CRAB) strains, is of great concern since the treatment options become limited. The "old" antibiotics including polymyxin B and colistin (polymyxin E) have now been reused as the last resort antibiotics for the treatment of serious infections with carbapenem-resistant Gram-negative bacteria. However, the increased use of colistin and improper understanding of its pharmacokinetics and pharmacodynamics have led to the emergence of colistin-resistant Gram-negative bacilli (Poirel et al. [@CR22]). A systematic review conducted on the studies across 41 countries showed that the global prevalence rates of colistin resistance in *A. baumannii* were 0.2--17.5% (Pormohammad et al. [@CR23]) with the levels as high as 30.6% in Korea (Ko et al. [@CR13]). Colistin heteroresistance, which is defined as the presence of resistant subpopulations within susceptible isolates, was also reported in this organism (Li et al. [@CR16]) with the rates ranging from 18.7 to 100% (Cai et al. [@CR3]). Treatment of infections caused by colistin-heteroresistant isolates may result in the selection of colistin-resistant subpopulations, thus leading to therapeutic failures (Hawley et al. [@CR10]).

In 2011, 10% of *A. baumannii* clinical isolates from a university hospital in central Thailand were colistin-resistant (Naksena et al. [@CR20]). In our hospital, this organism was the most common causative agent (approximately 20--30%) of hospital-acquired pneumonia and ventilator-associated pneumonia during 2008 and 2009 (Reechaipichitkul et al. [@CR24]). In this period, carbapenem resistance rate was more than 90% in *A. baumannii* isolates, thus leading to an increased use of colistin as a therapeutic option. In the same study, the colistin resistance rate in *A. baumannii* was 0.6%. However, there has been little information about colistin heteroresistance in Thai clinical isolates. The recommended colistin susceptibility testing, broth microdilution (BMD) method, is laborious and unable to detect colistin-heteroresistant strains in routine laboratory. A current standard method for detection of colistin heteroresistance is a population analysis profile (PAP) method, which is also laborious and time-consuming (Li et al. [@CR16]; Sherman et al. [@CR28]). Therefore, we investigated colistin heteroresistance rate in our colistin-susceptible CRAB clinical isolates by the PAP method. This would be baseline data and useful information for clinicians to be aware of the interpretation of colistin susceptibility results and use with caution.

Materials and methods {#Sec2}
=====================

Clinical isolates {#Sec3}
-----------------

A total of 75 non-duplicate colistin-susceptible CRAB isolates obtained from patients in Srinagarind Hospital, Khon Kaen University, Thailand between January and November in 2016 were included. They were from sputum or tracheal aspirates (46 isolates), pus (10 isolates), blood (3 isolates), drain fluid (2 isolates), others (urine, pleural fluid, tip cut down and stump, 1 isolate for each) and unknown sources (10 isolates). They were identified by conventional biochemical tests including glucose, citrate and malonate utilization, growth at 41 and 44 °C and the presence of hemolysis (Bouvet and Grimont [@CR1]), and then confirmed by the presence of an intrinsic *bla*~OXA-51-like~ (Turton et al. [@CR30]). All isolates were kept in skimmed milk with 15% glycerol at − 20 °C for further analysis.

MIC determination {#Sec4}
-----------------

Antimicrobial agents tested were amikacin and meropenem (Siam Bheasach, Bangkok, Thailand), gentamicin, ciprofloxacin, cefotaxime, ceftazidime and colistin (Sigma-Aldrich, St. Louis, MO, USA), imipenem (MSD, Whitehouse Station, NJ, USA), fosfomycin (Meiji Seika Pharma, Tokyo, Japan) and tigecycline (Pfizer Inc., Philadelphia, PA, USA). MICs of these antimicrobials were determined by agar dilution method except for that of colistin using the BMD method (CLSI [@CR5]). The MICs were interpreted according to the criteria of CLSI ([@CR5]) except for tigecycline using those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint (EUCAST [@CR7]). *Escherichia coli* ATCC 25922 was used as an antimicrobial-susceptible control strain.

Detection of carbapenemase genes {#Sec5}
--------------------------------

All isolates were screened for an intrinsic *bla*~OXA-51-like~, OXA carbapenemase (*bla*~OXA-23~, *bla*~OXA-24~, *bla*~OXA-58~ and *bla*~OXA-235~) and metallo-β-lactamase (*bla*~NDM~, *bla*~IMP~ and *bla*~VIM~) genes by PCR methods (Higgins et al. [@CR11]; Poirel et al. [@CR21]).

Modified population analysis profile (PAP) method {#Sec6}
-------------------------------------------------

All isolates were screened for colistin heteroresistance by the modified PAP method described by Li et al. ([@CR16]). A volume of 50 µL of each tenfold serial dilution (final inoculum of 10^2^ to 10^8^ CFU/mL) of bacterial suspension was spread onto Mueller Hinton agar (MHA) plates (Oxoid, Basingstoke, Hampshire, England) containing various concentrations of colistin (0, 0.5, 1, 2, 3, 4, 5, 6 and 8 µg/mL). Bacterial colonies were counted after 48-h incubation at 37 °C. Colistin heteroresistance was defined as the presence of a colistin-susceptible isolate with MIC of ≤ 2 µg/mL in which detectable colistin-resistant subpopulations were able to grow in the presence of \> 2 µg/mL of colistin (Yau et al. [@CR32]). Colistin MICs for the heteroresistant subpopulations were determined by the BMD method after 3 daily subculturing on antibiotic-free MHA plates. *Pseudomonas aeruginosa* ATCC 27853 was used as a colistin-susceptible control strain.

Strain typing {#Sec7}
-------------

The genetic relatedness of all isolates was investigated by enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) (Versalovic et al. [@CR31]). The fingerprints were verified by BioNumerics software (version 7.6, Applied Maths, Belgium) using the Dice coefficient and the unweighted pair group method of averages (UPGMA) with 1% optimization and 1% position tolerance. Isolates showing ≥ 80% similarity were considered clonally related (Ezadi et al. [@CR8]).

Results {#Sec8}
=======

Antimicrobial susceptibility {#Sec9}
----------------------------

All 75 CRAB isolates were susceptible to colistin with MICs ranging from 0.5 to 2 µg/mL (MIC~50~ and MIC~90~ of 1 and 2 µg/mL, respectively). Apart from colistin, amikacin was the second agent mostly active against the CRAB isolates with 25.3% susceptibility, whereas susceptibility to tigecycline was 2.7% only (Table [1](#Tab1){ref-type="table"}).Table 1MICs of various antimicrobials for the 75 colistin-susceptible CRAB isolatesAntimicrobial agents\
(concentrations tested, µg/mL)MICs (µg/mL)^a^%RangesMIC~50~MIC~90~SIRAmikacin (0.5--64)≤ 0.5 to 64 \> 64 \> 6425.31.373.4Gentamicin (0.25--32)≤ 0.25 to 32 \> 32 \> 3210.72.786.6Ciprofloxacin (0.004--32)2--32 \> 32 \> 3201.398.7Ceftazidime (0.125--256)8--256 \> 256 \> 2561.31.397.4Imipenem (0.125--256)16--256646400100Meropenem (0.125--256)16--2566412800100Fosfomycin (0.25--256)64--25612825610.753.336Tigecycline (0.031--32)0.5--16482.7--97.3Colistin (0.125--32)0.5--212100--0*S* susceptible, *I* intermediate, *R* resistant^a^MICs of all antimicrobials tested were determined by the agar dilution method except for those of colistin using the BMD method

Carbapenemase genes {#Sec10}
-------------------

All isolates contained the intrinsic *bla*~OXA-51-like~. Carbapenemase genes were found in 74 isolates (98.7%): 67 isolates with *bla*~OXA-23-like~, 2 isolates with *bla*~NDM-like~, 1 isolate with *bla*~OXA-58-like~, 3 isolates with both *bla*~OXA-23-like~ and *bla*~OXA-58-like~, and 1 isolate with both *bla*~OXA-23-like~ and *bla*~NDM-like~.

Colistin heteroresistance by modified PAP {#Sec11}
-----------------------------------------

Modified PAP analysis showed the growth of subpopulations in the presence of \> 2 µg/mL of colistin (Fig. [1](#Fig1){ref-type="fig"}). Of the 75 colistin-susceptible isolates, 35 isolates (46.7%) with colistin MICs of 1 (11 isolates) and 2 µg/mL (24 isolates) were identified as colistin-heteroresistant. After 3 daily passages through an antibiotic-free medium, colistin heteroresistance phenotype was maintained in 33 isolates (44%). They were from sputum or tracheal aspirates (25 isolates), pus (4 isolates), blood, drain fluid, tip cut down and tissue (1 isolate for each). The colistin MIC range for the 33 subpopulation isolates was 4- \> 32 µg/mL, with MIC~50~ and MIC~90~ of 32 and \> 32 µg/mL, respectively (Table [2](#Tab2){ref-type="table"}).Fig. 1Population analysis profiles of the CRAB clinical isolates with heteroresistant subpopulations (isolates A132, A212 and A275) and colistin susceptibility (isolate A87), and colistin-susceptible control strain (*P. aeruginosa* ATCC 27853)Table 2Characteristics of the 33 colistin-heteroresistant CRAB clinical isolatesNo. of isolatesCarbapenemase genesERIC\
patternsMICs (µg/mL)Resistant subpopulationsAKGCIPCZIPMEFSTGCTGrowth at colistin concentration\
(µg/mL)^a^Colistin MICs\
(µg/mL)^b^7*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 25632--6432--64128--2564--824--88- \> 323*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 2566464--128128--25621--24--832- \> 322*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 25664128128--25681--25--632- \> 322*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 25664--12864--128 \> 25621--258--161*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 2561664128413 \> 321*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 256256256128425 \> 321*bla*~OXA-23-like~Cluster C \> 64 \> 32 \> 32 \> 256128128 \> 256415 \> 321*bla*~OXA-23-like~Cluster C48 \> 32 \> 2563264128424 \> 321*bla*~OXA-23-like~ & *bla*~NDM-like~Cluster C \> 64 \> 32 \> 32 \> 256128128128423321*bla*~OXA-23-like~Cluster E4 \> 32 \> 32 \> 2563232256415 \> 321*bla*~OXA-23-like~Cluster E20.5 \> 32 \> 256323212822341*bla*~OXA-23-like~Cluster E \< 0.5 ≤ 0.2532 \> 2566464256226162*bla*~OXA-23-like~Cluster B \> 64 \> 32 \> 32 \> 25632--6432--642562--42832- \> 321*bla*~OXA-23-like~Cluster A48 \> 32166464256825 \> 321*bla*~OXA-23\ -like~ & *bla*~OXA-58-like~Cluster A8 \> 32 \> 32 \> 256643225642842*bla*~OXA-23-like~Cluster D116--32 \> 32643216--32128--25622832- \> 321*bla*~OXA-23-like~Cluster D \< 0.54812832161280.516 \> 321*bla*~OXA-23-like~ & *bla*~OXA-58-like~Singleton1 \> 32 \> 32 \> 2563232128418161*bla*~OXA-23-like~Cluster F44 \> 32 \> 25632321281628321*bla*~OXA-23\ -like~ & *bla*~OXA-58-like~Cluster F8 \> 32 \> 32 \> 2561632128162681*bla*~OXA-23-like~Singleton \> 64 \> 32 \> 32 \> 256646464414 \> 32*AK* amikacin, *CIP* ciprofloxacin, *CT* colistin, *CZ* ceftazidime, *G* gentamicin, *FS* fosfomycin, *IP* imipenem, *ME* meropenem, *TG* tigecycline^a^Highest colistin concentration that the isolate grew in the PAP method^b^MICs of heteroresistant subpopulations after 3 daily passages onto the colistin-free medium

Strain typing {#Sec12}
-------------

Cluster analysis using 80% similarity cut-off for clonal relatedness of the 75 CRAB isolates revealed 12 different ERIC-PCR patterns, 8 clusters and 4 singletons (data not shown). Thirty-eight isolates (50.7%) belonged to the same cluster. Among the 33 colistin-heteroresistant isolates, 6 clusters and 2 singletons were obtained (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Dendrogram of ERIC-PCR from the 33 colistin-heteroresistant CRAB clinical isolates generated by BioNumerics using the UPGMA and the Dice coefficient. Dashed line indicates 80% similarity cut-off

Discussion {#Sec13}
==========

Multidrug resistance (MDR) to currently available antibiotics in Gram-negative bacteria is the major problem of public health worldwide. A critical problem is the increasing prevalence of carbapenem resistance, particularly by the mechanism of carbapenemase production (Codjoe and Donkor [@CR6]). In this study, most of the CRAB isolates harbored one or two OXA carbapenemase genes, *bla*~OXA-23-like~ and/or *bla*~OXA-58-like~, similar to previous studies from Thailand (Lertsrisatit et al. [@CR18]; Leungtongkam et al. [@CR19]). In agreement with other reports, *bla*~OXA-23-like~ was the major resistance determinant (40--100%) among the CRAB isolates, indicating that carbapenem monotherapy is now no longer used as a therapeutic option against the MDR *A. baumannii* infections (Ezadi et al. [@CR8]; Salehi et al. [@CR27]).

Colistin has been used as the last resort for either MDR or extremely drug-resistant (XDR) *A. baumannii* infections (Cai et al. [@CR3]). However, colistin resistance in this organism has been reported globally. Furthermore, colistin heteroresistance was also discovered in 15 of 16 (93.8%) colistin-susceptible MDR *A. baumannii* isolates from Australia (Li et al. [@CR16]). Hawley et al. ([@CR10]) described colistin heteroresistance in 19 MDR *A. baumannii* clinical isolates from Texas between 2003 and 2005 as defined by their growth on plates containing 8 μg/mL of colistin and giving colistin MICs of \> 8 μg/mL, whereas Yau et al. ([@CR32]) reported the heteroresistance rate of 23% from Thailand in 2008. Colistin heteroresistance was also observed in 20 of 24 (83%) *A. baumannii* isolates obtained between 2013 and 2015 from the USA (Srinivas et al. [@CR29]). These isolates were from blood and respiratory tract, and susceptible to colistin with MICs of ≤ 0.25 to 0.5 µg/mL but grew on MHA containing 4 µg/mL of colistin. Recently, 9 of 44 (20.5%) colistin-susceptible CRAB isolates from northern Iran have been identified as colistin-heteroresistant with subpopulations growing in the presence of 6--8 µg/mL of colistin (Ezadi et al. [@CR8]). The colistin heteroresistance rates may be different due to inoculum size applied (10--100 μL) and cut-off for identifying heteroresistant subpopulations (4 or ≥ 8 μg/mL) (Hawley et al. [@CR10]; Li et al. [@CR16]; Srinivas et al. [@CR29]). Although colistin was the most active agent against the CRAB isolates in this study, colistin heteroresistance was observed in 44% of them as detected by the modified PAP method. Unfortunately, colistin-heteroresistant *A. baumannii* strains cannot be discriminated from colistin-susceptible strains by the standard BMD susceptibility testing (Ezadi et al. [@CR8]).

Impact of colistin heteroresistance on the clinical outcomes is of concern. The pharmacokinetic study has demonstrated that plasma colistin methanesulphonate concentrations usually achieve in the range of 1 to 4 µg/mL after intravenous administration (Li et al. [@CR15]). However, the treatment with low dose of colistin may not be effective and can cause the selection of heteroresistance. Increased colistin dose also leads to its nephrotoxicity. Hawley et al. ([@CR10]) demonstrated a statistically higher rate of colistin heteroresistance (7 from 19 isolates, 36.8%) among MDR *A. baumannii* isolates from patients with previous colistin exposure. Rodriguez et al. ([@CR25]) described the selection of colistin-resistant subpopulations from a colistin-heteroresistant *A. baumannii* isolate during the treatment with intrathecal colistin in a case of postneurosurgical meningitis. Gazel and Otkun ([@CR9]) also demonstrated that after sub-inhibitory exposure to colistin, heteroresistance or resistance had been developed in all CRAB isolates. In the present study, patients' clinical data and treatment outcomes, which may provide important information for the treatment of patients infected with colistin-heteroresistant CRAB isolates, were not available. However, we found the high rate of colistin heteroresistance among our CRAB isolates. It is possible that the colistin-resistant subpopulations from these isolates may be selected after exposure to colistin, leading to ineffective treatment. Therefore, combination therapies of colistin with other agents were suggested for patients infected with MDR *A. baumannii* isolates (Gazel and Otkun [@CR9]; Kengkla et al. [@CR12]; Rodriguez et al. [@CR26]).

The main mechanism of colistin resistance in *A. baumannii* is the modification of lipopolysaccharide (LPS) by mutations in PmrA/PmrB two-component system (Ko et al. [@CR14]). These mutations cause upregulation of the *pmrCAB* operon, which results in the synthesis and addition of positively charged phosphoethanolamine to the LPS. An increase in positive charge of the LPS leads to a decrease in the binding between colistin (positive charge) and lipid A (negative charge) of the LPS, thus resulting in colistin resistance. Mutations in PmrB such as S144KLAGS, P170L and M308R, and that in PmrA such as M12I were responsible to colistin heteroresistance (Charretier et al. [@CR4]). Unfortunately, molecular resistance mechanisms of the colistin-heteroresistant CRAB isolates were not investigated in the present study.

In conclusion, the rate of colistin heteroresistance was high (44%) among the CRAB clinical isolates from our hospital. They were of different strains and their subpopulations exhibited high-level colistin resistance. This highlights that clinical use of colistin for the treatment of the CRAB infections may be failure because of the selection of heteroresistant subpopulations.
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